Unknown

Dataset Information

0

Effects of Single and Repeated Oral Doses of Ochratoxin A on the Lipid Peroxidation and Antioxidant Defense Systems in Mouse Kidneys.


ABSTRACT: Ochratoxin-A (OTA) is a carcinogenic and nephrotoxic mycotoxin, which may cause health problems in humans and animals, and it is a contaminant in foods and feeds. The purpose of the present study is to evaluate the effect of oral OTA exposure on the antioxidant defense and lipid peroxidation in the kidney. In vivo administration of OTA in CD1, male mice (1 or 10 mg/kg body weight in a single oral dose for 24 h and repeated daily oral dose for 72 h or repeated daily oral dose of 0.5 mg/kg bodyweight for 21 days) resulted in a significant elevation of OTA levels in blood plasma. Some histopathological alterations, transcriptional changes in the glutathione system, and oxidative stress response-related genes were also found. In the renal cortex, the activity of the glutathione-system-related enzymes and certain metabolites of the lipid peroxidation (conjugated dienes, trienes, and thiobarbituric reactive substances) also changed.

SUBMITTER: Ferenczi S 

PROVIDER: S-EPMC7700583 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of Single and Repeated Oral Doses of Ochratoxin A on the Lipid Peroxidation and Antioxidant Defense Systems in Mouse Kidneys.

Ferenczi Szilamér S   Kuti Dániel D   Cserháti Mátyás M   Krifaton Csilla C   Szoboszlay Sándor S   Kukolya József J   Szőke Zsuzsanna Z   Albert Mihály M   Kriszt Balázs B   Kovács Krisztina J KJ   Mézes Miklós M   Balogh Krisztián K  

Toxins 20201122 11


Ochratoxin-A (OTA) is a carcinogenic and nephrotoxic mycotoxin, which may cause health problems in humans and animals, and it is a contaminant in foods and feeds. The purpose of the present study is to evaluate the effect of oral OTA exposure on the antioxidant defense and lipid peroxidation in the kidney. In vivo administration of OTA in CD1, male mice (1 or 10 mg/kg body weight in a single oral dose for 24 h and repeated daily oral dose for 72 h or repeated daily oral dose of 0.5 mg/kg bodywei  ...[more]

Similar Datasets

| S-EPMC1135495 | biostudies-other
| S-EPMC3652298 | biostudies-literature
| S-EPMC3828286 | biostudies-literature
| S-EPMC3890749 | biostudies-other
| S-EPMC3901711 | biostudies-literature
| S-EPMC5319403 | biostudies-literature
| S-EPMC8393662 | biostudies-literature
| S-EPMC7574533 | biostudies-literature
| S-EPMC7143643 | biostudies-literature